Becton, Dickinson and Company, with its diversified offerings in medical supplies and healthcare solutions, presents a moderate investment opportunity. Its strong position in the healthcare sector provides some cushion against economic fluctuations. However, investors should be aware of regulatory risks and competition in the medical technology field.
BDX has a fundamental rating of B, with varied performance across critical financial metrics.
| Category | Score | Rating |
|---|---|---|
| Discounted Cash Flow | 5 | |
| Return on Equity | 3 | |
| Return on Assets | 4 | |
| Debt to Equity | 1 | |
| Price to Earnings | 1 | |
| Price to Book | 3 |
The historical scores for BDX indicate resiliency over time, with steady performance in core areas.
| Date | Overall Score | DCF | ROE | ROA | Debt to Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-05-15 | 3 | 5 | 3 | 4 | 1 | 1 | 3 |
| Previous | 0 | 5 | 3 | 4 | 1 | 1 | 3 |
The price targets for BDX suggest a conservative outlook with a hold consensus among analysts.
| High | Low | Median | Consensus |
|---|---|---|---|
| 204 | 159 | 168.01 | 173.19 |
Analyst sentiment reflects mixed opinions with a predominant hold stance.
| Recommendation | Number | Percentage |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 16 | |
| Hold | 17 | |
| Sell | 1 | |
| Strong Sell | 0 |
Becton, Dickinson and Company offers stable growth in the healthcare sector, backed by its comprehensive product range. The stock's current valuation is moderate, with a consistent historical performance in key financial metrics. Analyst sentiments suggest a hold position, indicating market confidence in its business continuity but highlighting potential regulatory pressures. Investors can consider BDX for diversification, keeping a cautious eye on competitive forces. Long-term prospects remain promising due to its innovation-driven ethos.
Don't leave your profits to chance. Historically, this stock follows specific seasonal patterns that institutional traders use to maximize returns.